Julphar Bangladesh launches Doxair 200 for easy breathing

On March 8th, 2017 Julphar Bangladesh launched Doxair 200 (Doxophylline 200 mg), a novophylline ensuring easy breathing and indicated for the treatment of asthma, Chronic Obstructive Pulmonary Disease (COPD) and bronchospasm.

 

Doxophylline is a new generation xanthine derivative which has a dioxolane group at N-7 position of its chemical structure. Doxophylline inhibits phosphodiesterase activities and appears to have a less affinity towards adenosine A1 and A2 receptors, which is account for the better safety profile of the drug.

 

The launch is part of Julphar Bangladesh’s mission to contribute to the improvement of people’s quality of life in the country and to the development of the healthcare community.